Extranodal primary CD20-negative diffuse large B-cell lymphoma with cytoplasmic p16 expression
DOI:
https://doi.org/10.15419/bmrat.v9i6.743Keywords:
CD20-negative diffuse large B-cell lymphoma, biomarkers p16 of cellular senescence, double/triple expressors, immunohistochemistryAbstract
Extranodal primary CD20-negative diffuse large B-cell lymphoma (DLBCL) is a rare tumor. It often presents a diagnostic challenge for pathologists as the morphological features of neoplastic cells are similar to those of undifferentiated carcinoma or sarcoma cells. While several B-cell markers are commonly tested, expanding the panel of B-cell markers is necessary to ascertain definitive DLBCL diagnoses and would assist in decisions regarding treatment and prognoses. Several additional markers have been proposed, including several mutated genes commonly expressed in cancer cells, such as c-Myc, Bcl6/c-Myc, Bcl6, Bcl2 (double/triple expressors), as well as cytoplasmic p16.
Published
Issue
Section
License
Copyright The Author(s) 2017. This article is published with open access by BioMedPress. This article is distributed under the terms of the Creative Commons Attribution License (CC-BY 4.0) which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
